Strategic Partnerships Epic Sciences collaborates with leading pharmaceutical companies and major cancer centers, indicating a ready-made path for co-development, clinical validation, and expanded distribution of liquid biopsy diagnostics.

Series G Momentum Recent $24M Series G funding from Deerfield Management and Arsenal Capital Partners signals strong investor confidence and potential for accelerated commercialization, allowing for scale-up of sales reach and reimbursement discussions.

Product Portfolio Launch of DefineMBC and a liquid biopsy platform for circulating tumor cells positions Epic to target metastatic breast cancer and broader oncology indications, offering opportunities for diagnostic adoption in clinical workflows and trial enrollment.

Clinical Impact The technology enables non-invasive detection of genetic and molecular changes and monitoring of drug resistance, providing sales angles around precision medicine, treatment personalization, and real-time decision support for physicians.

Market Positioning With a focused team size and revenue in the multi-tens of millions, Epic Sciences sits between early-stage biotech and large CROs, presenting opportunities to engage mid-sized biopharma companies seeking differentiated diagnostics for partner-led trials.